Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Silence sets up SAB to strengthen liver pipeline

This article was originally published in Scrip

Executive Summary

RNA interference company Silence Therapeutics has created a scientific advisory board with the appointment of two key opinion leaders in the area of liver diseases, Professors Detlef Schuppan and Massimo Pinzani. Professor Schuppan is a consultant gastroenterologist and hepatologist, director of molecular and translational medicine, and full professor of medicine at Mainz University Medical Centre in Germany. He is also professor of medicine and senior visiting scientist at Harvard Medical School. Professor Pinzani is professor of medicine and gastroenterology at the University of Florence, Italy, and visiting professor in the division of hepatology at Osaka City School of Medicine in Japan.

You may also be interested in...

Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts